Palvella Therapeutics (PVLA) Other Gross PP&E Adjustments (2013 - 2026)
Palvella Therapeutics (PVLA) reported Other Gross PP&E Adjustments of -$853000.0 for Q1 2026, down 71.63% year-over-year from -$3.0 million in Q1 2025, and up 22.67% quarter-over-quarter from -$1.1 million in Q4 2025.
Palvella Therapeutics (PVLA) Other Gross PP&E Adjustments (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has 14 years of Other Gross PP&E Adjustments data on file, last reported at -$853000.0 in Q1 2026.
- Other Gross PP&E Adjustments for Q1 2026 came in at -$853000.0, down 71.63% year-over-year; the trailing twelve-month figure through Mar 2026 was -$853000.0 (down 71.63% YoY), and the FY2025 annual result was -$1.1 million, down 36.51% from the prior year.
- Other Gross PP&E Adjustments advanced to -$853000.0 in Q1 2026 per PVLA's latest filing, from -$1.1 million in the prior quarter.
- Over five years, Other Gross PP&E Adjustments peaked at $23.2 million in Q1 2022 and troughed at -$1.1 million in Q4 2025.
- A 5-year average of $10.0 million and a median of -$399000.0 in 2025 frame the typical range for Other Gross PP&E Adjustments.
- The sharpest annual moves came in 2023 and 2024: Other Gross PP&E Adjustments sank 104.19% in 2023, then gained 15.83% in 2024.
- A 5-year view of Other Gross PP&E Adjustments shows it stood at $22.9 million in 2022, then sank by 104.19% to -$960000.0 in 2023, then grew by 15.83% to -$808000.0 in 2024, then tumbled by 36.51% to -$1.1 million in 2025, then advanced by 22.67% to -$853000.0 in 2026.
- Business Quant data shows PVLA's Other Gross PP&E Adjustments at -$853000.0 in Q1 2026, -$1.1 million in Q4 2025, and -$614000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -60,691.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -83,048.00 |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -285.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -892,000.00 |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -1.69 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Palvella Therapeutics | 1.42 Bn | 1.16 Bn | - | -853,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -853,000.00 |
| Mar 31, 2026 | -853,000.00 |
| Dec 31, 2025 | -1.10 Mn |
| Dec 31, 2025 | -1.10 Mn |
| Sep 30, 2025 | -614,000.00 |
| Sep 30, 2025 | -614,000.00 |
| Jun 30, 2025 | -399,000.00 |
| Jun 30, 2025 | -399,000.00 |
| Mar 31, 2025 | -497,000.00 |
| Mar 31, 2025 | -497,000.00 |
| Dec 31, 2024 | -808,000.00 |
| Dec 31, 2024 | -808,000.00 |
| Dec 31, 2023 | -960,000.00 |
| Dec 31, 2023 | -960,000.00 |
| Jun 30, 2023 | 22.87 Mn |
| Jun 30, 2023 | 22.87 Mn |
| Mar 31, 2023 | 22.88 Mn |
| Mar 31, 2023 | 22.88 Mn |
| Dec 31, 2022 | 22.93 Mn |
| Dec 31, 2022 | 22.93 Mn |